Leaflet GRAZAX 75000 SQ-T oral lyophilisate


Indicated for: allergy diagnosis; allergen immunotherapy

Route of administration: oral

Substance: grass pollen (diagnostic agent)

ATC: V01AA02 (Various | Allergens | Allergen extracts)

Grass pollen is a common cause of seasonal allergies, affecting many people during spring and summer. It is produced by grasses and other plants in the Poaceae family and can trigger symptoms such as sneezing, nasal congestion, itching, and watery eyes.

To reduce exposure to grass pollen, it is recommended to avoid outdoor activities during the pollination season, use air filters, and frequently wash clothes and hair. In severe cases, antihistamines or immunotherapy may be necessary.

Side effects of pollen exposure may include worsening of asthma or other respiratory conditions. It is important to consult a doctor if symptoms become severe or persist.

People allergic to grass pollen should monitor pollen forecasts and take preventive measures to reduce discomfort.

General data about GRAZAX 75000 SQ-T

  • Substance: grass pollen
  • Date of last drug list: 01-03-2022
  • Commercial code: W68401002
  • Concentration: 75000SQ-T
  • Pharmaceutical form: oral lyophilisate
  • Quantity: 90
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ALK-ABELLÓ S.A. - SPANIA
  • Holder: ALK-ABELLÓ A/S - DANEMARCA
  • Number: 14141/2021/02
  • Shelf life: 5 years

Pharmaceutical forms available for grass pollen

Concentrations available for grass pollen

  • 10HEP
  • 75000SQ-T